SBRT with concurrent chemoradiation in stage III NSCLC: first results of the phase I Hybrid trial

被引：0
|
作者：
Peulen, H. [1 ]
Sonke, J. J. [1 ]
Van der Bijl, E. [1 ]
Damen, E. [1 ]
Belderbos, J. [1 ]
机构：
[1] Netherlands Canc Inst, Radiat Oncol, Amsterdam, Netherlands
来源：
RADIOTHERAPY AND ONCOLOGY | 2016年 / 119卷
关键词：
D O I：
10.1016/S0167-8140(16)31526-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PV-0277
引用
收藏
页码：S129 / S129
页数：1
相关论文
共 50 条
  • [1] SBRT combined with concurrent chemoradiation in stage III NSCLC: Feasibility study of the phase I Hybrid trial
    Peulen, Heike
    Franssen, Gijs
    Belderbos, Jose
    van der Bijl, Erik
    Tijhuis, Angela
    Rossi, Maddalena
    Sonke, Jan-Jakob
    Damen, Eugene
    RADIOTHERAPY AND ONCOLOGY, 2020, 142 : 224 - 229
  • [2] Updated Results of a Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Patients with Unresectable Stage III NSCLC
    Durm, G.
    Althouse, S.
    Sadiq, A.
    Jalal, S.
    Jabbour, S.
    Zon, R.
    Kloecker, G.
    Fisher, W.
    Reckamp, K.
    Kio, E.
    Langdon, R.
    Adesunloye, B.
    Gentzler, R.
    Hanna, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S321 - S321
  • [3] NRG LU008: Phase III Randomized Trial of Primary Tumor SBRT Followed by Concurrent Mediastinal Chemoradiation for LA-NSCLC
    Heinzerling, J.
    Hu, C.
    Simone, C. B., II
    Mileham, K. F.
    Higgins, K. A.
    Lin, L.
    Abazeed, M. E.
    Ohri, N.
    Bradley, J. D.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S339 - S339
  • [4] Phase I trial of proteasome inhibition with bortezomib (BOR) with concurrent chemoradiation (chemoXRT) for stage III non-small cell lung cancer (NSCLC).
    Suntharalingam, M
    Edelman, MJ
    Kwong, K
    Smith, R
    Bedor, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 695S - 695S
  • [5] Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC
    Lin, Steven H.
    Lin, Yan
    Yao, Luyang
    Kalhor, Neda
    Carter, Brett W.
    Altan, Mehmet
    Blumenschein, George
    Byers, Lauren A.
    Fossella, Frank
    Gibbons, Don L.
    Kurie, Jonathan M.
    Lu, Charles
    Simon, George
    Skoulidis, Ferdinandos
    Chang, Joe Y.
    Jeter, Melenda D.
    Liao, Zhongxing
    Gomez, Daniel R.
    O'Reilly, Michael
    Papadimitrakopoulou, Vali
    Thall, Peter
    Heymach, John V.
    Tsao, Anne S.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) : 248 - 257
  • [6] IMAGE GUIDED SBRT USING TOMOTHERAPY FOR STAGE I NSCLC: FIRST CLINICAL RESULTS
    Vonk, Ernest J. A.
    Minken, Andre
    Ten Brinke, Marloes I.
    Noordhoek, Margo C.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S804 - S804
  • [7] Blood lymphocytes as a prognostic factor for stage III NSCLC with concurrent chemoradiation.
    Kim, Yong-Hyub
    Ahn, Sung-Ja
    Nam, Taek-Keun
    Yoon, Meesun
    Jeong, Jae-Uk
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S1676 - S1677
  • [8] Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC
    Ross, Helen J.
    Kozono, David E.
    Urbanic, James John
    Williams, Terence Marques
    Dufrane, Carter
    Bara, Ilze
    Gandhi, Mayank
    Schulze, Katja
    Brockman, Jane Michelle
    Wang, Xiaofei F.
    Vokes, Everett E.
    Stinchcombe, Tom
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Prospective Phase I Dose Escalation Results of SBRT for Centrally-located Stage I NSCLC
    Bradley, J. D.
    Robinson, C.
    Parikh, P.
    Bien-Willner, L.
    DeWees, T.
    Gao, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S79 - S79
  • [10] Ph I Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and SBRT to Multiple Sites in Patients with Stage IV NSCLC
    Patel, J.
    Jelinek, M.
    Bestvina, C.
    Pitroda, S.
    Vokes, E.
    Chmura, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S712 - S712
12345